European Commission approves Roche's Susvimo as Roche Holding stock trades EUR 372.58
Published on 10/03/2026 at 12:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 21, 2026, the European Commission approved Roche's Susvimo, according to Roche's media releases. Roche Holding stock was quoted at EUR 372.58 in weekend trading at Lang & Schwarz at 12:40 p.m. CEST on October 3, 2026.
Weekend trading
Lang & Schwarz listed a bid of EUR 371.95 and an ask of EUR 373.20 for Roche Holding at 12:40 p.m. CEST on October 3, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Roche Holding stock.
Roche development
Roche's September 21 release said the European Commission had approved Susvimo. The Roche media release identified the product as the company's treatment for neovascular age-related macular degeneration. The announcement is dated September 21, 2026, and is published on Roche's official media-release page.
Next Xetra session
Xetra remains closed on October 3, 2026. The next Xetra session is scheduled for October 5, 2026.
